Lifestyle weight-loss intervention may attenuate methylation aging: the CENTRAL MRI randomized controlled trial

摘要: DNA methylation age (mAge), a biomarker for the aging process, might serve as more accurate predictor of morbidity and status than chronological age. We evaluated role multiple factors, including fat deposition, cardiometabolic risk factors lifestyle weight-loss intervention, on deviation mAge from (mAge deviation) or 18-month change in (∆mAge). In this sub-study CENTRAL magnetic resonance imaging trial, we by validated 240-CpG-based prediction formula at baseline after intervention either low (LF) mediterranean/low carbohydrate (MED/LC) diets. Among 120 participants with abdominal obesity dyslipidemia, (mean ± SD: 60.3 ± 7.5 years) was higher (48.6 ± 9.3 years) but strongly correlated (r = 0.93; p = 3.1 × 10–53). Participants lowest tertile their had significantly lower waist-circumference, visceral adipose tissue, intrahepatic (IHF) content, fasting-glucose HOMA-IR, compared highest sex-specific residual (p   5% weight loss) vs. failures ( ∆ = 0.6 years ∆ = 1.1 years; p = 0.04), who completed trial healthy liver content (< 5% IHF) fatty (∆ = 0.6 years ∆ = 1.8 years; p = 0.003). Overall, 18 months attenuated mAging men, mainly older, 7.1 months expected (p < 0.05). Lifestyle may attenuate mAging. Deviation be related to body distribution glycemic control could indicate biological age, health premature diseases. Trial registration: ClinicalTrials.gov NCT01530724. Registered 10 February 2012, https://clinicaltrials.gov/ct2/show/study/NCT01530724 .